Interview part two: Chang Yi Wang, Chairperson & CEO, UBI Asia, and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
The company’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on UBI’s proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The company’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the company’s subsidiary UBI-Asia and various sponsorships in product development.
Rm. E, 52F., No.7-5,
Sec. 5, Xinyi Rd.,
Xinyi Dist.,
Taipei City
11049,
Taiwan (R.O.C.)
Tel:886-2-8101-0101
Fax:886-2-8101-0100
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
Carol Cheng, COO of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), provides insights into the recent development of the country’s innovative biopharmaceutical industry, while she also highlights TRPMA’s eye-catching initiative…
Carol Cheng, COO of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), the association gathering 28 Taiwan-based, R&D-driven biopharmaceutical companies, highlights the association’s eye-catching initiative to boost international collaboration between academia…
James Chen, founder and Chairman of the board of Vetco, the first Taiwan-based veterinary company to have successfully developed an innovative veterinary oncology product, documents the main specificities of Vetco’s…
Johnsee Lee, founder, CEO, and president of Personal Genomics and its sister company Quark Biosciences, provides insights into the company’s proprietary Optoelectronic Sequencing (OES) technology, which can perform whole genome…
Ben Chien, Chairman, President and CEO, of Foresee Pharmaceuticals, one of Taiwan’s most vibrant success stories, discusses how Foresee has achieved successful phase III results for its prostate cancer treatment,…
Dr. Hui-Ting Huang, President of Taiwan Adventist Hospital, discusses the challenges of long-term care and the role preventive medicine plays within this scope, while also providing insights on running one…
Dr. Tzu-Ling (Karen) Tseng, CEO of Bio Preventive Medicine Corporation in Taiwan, discusses the innovative technology of its patented biomarkers, the success of DNlite and company’s strategy to grow through…
C.Y. Cheng, chairman and president of Formosa Laboratories, shares exciting news about the establishment of a new drug development company, Formosa Pharmaceuticals. He explains how the know-how gained from running…
With 7,000 employees in 25 locations across 12 countries in the region, PAREXEL now has more than a third of its global staff in Asia Pacific (APAC). Albert Liou, Vice…
Chih-Yi Weng, chairlady and CEO of Charsire Biotechnology, one of Taiwan’s leading biotech companies focused on the development of botanical new drugs as well as topical and personal care products,…
Peter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s…
Peter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s…
See our Cookie Privacy Policy Here
